Pharmaceutical care program for type 2 diabetes patients in Brazil: A randomised controlled trial

International Journal of Clinical Pharmacy

Volumn 35, Issue 1, 2013, Pages 79-86

  Mourão, Aline Oliveira Magalhães ^a   Ferreira, Wandiclécia Rodrigues ^a   Martins, Maria Auxiliadora Parreiras ^b   Reis, Adriano Max Moreira ^b   Carrillo, Maria Ruth Gaede ^a   Guimarães, Andrea Grabe ^a   Ev, Lisiane Silveira ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Brazil; Diabetes mellitus; Diabetes type 2; Pharmaceutical care; Pharmacists; Randomised controlled trial

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAZIL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BRAZIL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL SERVICES;

EID: 84874656910     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9710-7     Document Type: Article

References (28)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
2. Malerbi DA, Franco LJ. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 years. The Brazilian Cooperative Group on the Study of Diabetes Prevalence. Diabetes Care. 1992;15:1509-16.
3. Sociedade Brasileira de Diabetes (SBD). Diretrizes da Sociedade Brasileira de Diabetes. [cited 2012 18 Jul]; Available from: http://www.diabetes.org.br/attachments/diretrizes09-final.pdf.
4. Brasil. Saúde Brasil 2009: uma análise da situação de saúde e da agenda nacional e internacional de prioridades em saúde. [cited 2012 18 Jul]; Available from: http://portal.saude.gov.br/portal/arquivos/pdf/29-11-10-saude-brasil-web.pdf.
5. Mendes ABV, Fittipaldi JAS, Neves RCS, Chacra AR, Moreira ED. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta Diabetol. 2010;47:137-45.
6. World Health Organization. The role of the pharmacist in the health care system. Vancouver, Canada; 1997. [cited 2012 18 Jul]; Available from: www.opas.org.br/medicamentos/site/UploadArq/who-pharm-97-599.pdf.
7. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533-43.
8. Turnacilar M, Sancar M, Apikoglu-Rabus S, Hursitoglu M, Izzettin FV. Improvement of diabetes indices of care by a short pharmaceutical care program. Pharm World Sci. 2009;31:689-95.
9. Fornos AJ, Andrés NF, Andrés JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci. 2006;28:65-72.
10. Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J, et al. The pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24:677-83.
11. Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2005;28:771-6.
12. Correr CJ, Melchiors AC, Fernandes-Llimós F, Pontarolo R. Effects of a pharmacotherapy follow-up in community pharmacies on type 2 diabetes patients in Brazil. Int J Clin Pharm. 2011;33:273-80.
13. Neto PRO, Marusic S, Lyra-Júnior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 36-month pharmaceutical care program on coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharmaceut Sci. 2011;14:249-63.
14. Borges AP, Guidoni CM, Ferreira LD, de Freitas O, Pereira LR. The pharmaceutical care of patients with type 2 diabetes mellitus. Pharm World Sci. 2010;32:730-6.
15. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67:547-57.
16. Correr CJ, Pontarolo R, Wiens A, Rossignoli P, Melchiors AC, Radominski R, et al. Economic evaluation of pharmacotherapeutic follow-up in type 2 diabetes mellitus patients in community pharmacies. Arq Bras Endocrinol Metab. 2009;53:825-33.
17. Cid AS. Avaliação da efetividade da atenção farmacêutica no controle da hipertensão arterial. Dissertação (Mestrado em Ciências Farmacêuticas). Universidade Federal de Ouro Preto, Ouro Preto; 2008.
18. World Health Organization. ATC/DDD Index 2010. [cited 2012 18 Jul]; Available from: http://www.whocc.no/atc-ddd-index/.
19. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem. 1972;18:499-502.
20. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34(Suppl. 1):S11-61.
21. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician's guide. 2nd ed. New York: McGraw-Hill; 2004.
22. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
23. Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: final economic and clinical results. J Am Pharm Assoc. 2009;49(3):383-91.
24. Ivama AM, Noblat L, De Castro MS, De Oliveira NVBV, Jaramillo NM, Rech N. Consenso Brasileiro de atenção farmacêutica. Brasília: PAHO/WHO; 2002.
25. Peduzzi M. Multiprofessional healthcare team: concept and typology. Rev Saúde Pública. 2001;35:103-9.
26. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337-42.
27. Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes. 2010;4:203-7.
28. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-34.